ClinicalTrials.gg
TerminatedNCT06346704NHS-MS-EGYPTUpdated Dec 15, 2025

Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis

An observational study in Multiple Sclerosis, sponsored by SYSNAV. Terminated at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by SYSNAV · Observational

How we know

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
86
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Multiple Sclerosis with a site in Egypt — 9 open to participants now, 12 under way, none of them phase 3. Multiple Sclerosis · Egypt.

Enrollment
14th of 22
86 · median 100
Started
2024
with 4 others
Observational
22 of 51
4 open now
Registered
34th of 51
by date

Among the 51 studies in Multiple Sclerosis with a site in Egypt, this one is the 14th largest by enrollment of the 22 observational ones that give a count, is one of 5 that started in 2024, is one of 22 observational ones, and was the 34th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 51 studies in Multiple Sclerosis with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Multiple Sclerosis with a site in Egypt, or all of them as a file.
02

Study summary

The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Digital Health Technology
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects followed for multiple sclerosis care at the investigational site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject aged from 18 to 65 years old.
  2. Signed and ability to comply with study and follow-up.
  3. Diagnosed with MS base on 2017 McDonald criterion
  4. EDSS ≤ 5.5
  5. No clinical or radiological relapse within the last 3 months
  6. For patient under treatment, the molecule and its dose should be stable about 2 months before inclusion
  7. Subject willing and able to comply to all study procedures including the Syde® related ones

Exclusion criteria

Exclusion Criteria:

  1. Patient with a cognitive or communicational disorder disturbing the understanding of the tasks or data collection
  2. Previous or current disorder with an impact on current ambulation or motor function
  3. Patient who have had surgery or traumatic injury in upper or lower limb within the last 6 months before the inclusion or patients who have had major surgery or trauma within the last 6 months before the inclusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
86 participants (actual)
Patient registry
No

Interventions

  • OtherDigital HealthTechnology

    Subject will wear the Syde® for 1 month every 6 months

    Also known as: Syde®

06

What researchers measure

Primary outcomes

  1. Longitudinal change of 95th centile of stride velocity

    change between baseline and Month 6, Month 12, Month 18 and Month 24

    Time frame: 2 years

Secondary outcomes

  1. Correlation of the Syde® variables with the clinical assessments EDSS, FSS and T25FWT

    Time frame: 2 years

07

Study locations

1 site
  • Air Force Specialized Hospital
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Apr 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 4, 2024
StartActual
Apr 25, 2024
Primary completionActual
Apr 25, 2025
CompletionActual
Apr 25, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06346704
Lead sponsor
SYSNAV
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Apr 25, 2024
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025
Last update
Dec 15, 2025

Study contacts

Ahmed Elnemr, MD
principal investigator · Air Force Specialized Hospital Cairo

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion